# Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation

> **NCT06759909** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 100 (estimated)

## Conditions studied

- Dapagliflozin (Forxiga)
- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** Dapagliflozin (DAPA)

## Key facts

- **NCT ID:** NCT06759909
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2026-12-22
- **Final completion:** 2028-12-22
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759909, "Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06759909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*